AEM vs KALU

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

KALU presents a stark contrast between aggressive growth and deteriorating operational health, highlighted by a weak Piotroski F-Score of 3/9. While the company exhibits strong top-line growth (21.4% YoY) and an impressive ROE of 14.34% relative to its sector, the current price of $142.67 trades at a significant premium to its Graham Number of $88.58. The bullish growth-based intrinsic value of $200.01 is countered by bearish technical trends (10/100) and negative insider sentiment. Consequently, the stock appears overextended in the short term despite strong fundamental growth metrics.